Molecular Biology Reports

, Volume 44, Issue 1, pp 129–137 | Cite as

Suppression of mTOR signaling pathway promotes bone marrow mesenchymal stem cells differentiation into osteoblast in degenerative scoliosis: in vivo and in vitro

  • Yu Wang
  • Xiao-Dong Yi
  • Chun-De LiEmail author
Original Article


To investigate the role of mTOR signaling pathway in bone marrow mesenchymal stem cells (BMSCs) differentiation into osteoblast in degenerative scoliosis (DS). The rat model of DS was established. Thirty-two Sprague–Dawley (SD) rats were selected and divided into the normal control group, the positive control group (normal rats injected with rapamycin), the negative control group (DS rats injected with PBS) and the experiment group (DS rats injected with rapamycin). H&E staining was performed to observe the osteogenesis of scoliosis. The BMSCs were obtained and assigned into seven groups: the normal control group, the positive control group, the negative control group and 1.0/10.0/100.0/1000.0 nmol/L experiment groups. Flow cytometry was conducted to testify cell cycle. The mRNA and protein expressions of mTOR and osteoblastic differentiation markers were measured by qRT-PCR and western blotting. In vivo, compared with the negative control group, bone trabecular area and the number of differentiated bone cells were significantly increased in the experiment groups. In vitro, at 24 and 48 h after rapamycin treatment, compared with the negative control group, BMSCs at G0/G1 stage increased, but BMSCs at S stage decreased in the 1.0/10.0/100.0/1000.0 nmol/L experiment groups; the expressions of mTOR and p70-S6K1 proteins were reduced in the 1.0/10.0/100.0/1000.0 nmol/L experiment groups, while ALP activity, OC levels, calcium deposition, Co1-I protein expression and the mRNA expressions of OC and Co1-I were significantly increased. Suppression of mTOR signaling pathway by rapamycin could promote BMSCs differentiation into osteoblast in DS.


mTOR signaling pathway Bone marrow mesenchymal stem cells Differentiation Degenerative scoliosis Osteoblast In vivo In vitro 



The authors would like to thank the reviewers for their constructive comments.

Compliance with ethical standards

Conflict of interest



  1. 1.
    Zheng J, Yang Y, Zhao K, Wang R (2015) Low expression of microRNA-143 is related to degenerative scoliosis possibly by regulation of cyclooxygenase-2 expression. Int J Clin Exp Med 8(3):4140–4145PubMedPubMedCentralGoogle Scholar
  2. 2.
    Zhu Y, Wang K, Wang B, Wang H, Jin Z, Zhu Z, Liu H (2015) Selection of proximal fusion level for degenerative scoliosis and the entailing proximal-related late complications. Int J Clin Exp Med 8(4):5731–5738PubMedPubMedCentralGoogle Scholar
  3. 3.
    Kotwal S, Pumberger M, Hughes A, Girardi F (2011) Degenerative scoliosis: a review. HSS J 7(3):257–264CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Han S, Zhu Y, Wu Z, Zhang J, Qiu G (2013) The differently expressed proteins in MSCs of degenerative scoliosis. J Orthop Sci 18(6):885–892CrossRefPubMedGoogle Scholar
  5. 5.
    Li D, Wang C, Chi C, Wang Y, Zhao J, Fang J, Pan J (2016) Bone marrow mesenchymal stem cells inhibit lipopolysaccharide-induced inflammatory reactions in macrophages and endothelial cells. Mediators Inflamm 2016:2631439PubMedPubMedCentralGoogle Scholar
  6. 6.
    Laplante M, Sabatini DM (2012) mTOR signaling in growth control and disease. Cell 149(2):274–293CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Zoncu R, Efeyan A, Sabatini DM (2011) mTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 12(1):21–35CrossRefPubMedGoogle Scholar
  8. 8.
    Urbanska M, Gozdz A, Swiech LJ, Jaworski J (2012) Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J Biol Chem 287(36):30240–30256CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Prasad G, Sottero T, Yang X, Mueller S, James CD, Weiss WA, Polley MY, Ozawa T, Berger MS, Aftab DT, Prados MD, Haas-Kogan DA (2011) Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol 13(4):384–392CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Awasthi N, Yen PL, Schwarz MA, Schwarz RE (2012) The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem 113(3):784–791CrossRefPubMedGoogle Scholar
  11. 11.
    Huang X, Zeng Y, Wang X, Ma X, Li Q, Li N, Su H, Huang W (2016) FXR blocks the growth of liver cancer cells through inhibiting mTOR-s6K pathway. Biochem Biophys Res Commun 474(2):351–356CrossRefPubMedGoogle Scholar
  12. 12.
    Zhang Z, Yang M, Wang Y, Wang L, Jin Z, Ding L, Zhang L, Zhang L, Jiang W, Gao G, Yang J, Lu B, Cao F, Hu T (2016) Autophagy regulates the apoptosis of bone marrow-derived mesenchymal stem cells under hypoxic condition via AMP-activated protein kinase/mammalian target of rapamycin pathway. Cell Biol Int 40(6):671–685CrossRefPubMedGoogle Scholar
  13. 13.
    Gharibi B, Farzadi S, Ghuman M, Hughes FJ (2014) Inhibition of Akt/mTOR attenuates age-related changes in mesenchymal stem cells. Stem Cells 32(8):2256–2266CrossRefPubMedGoogle Scholar
  14. 14.
    Yang C, Li Y, Zhao Y, Zhu X, Li M, Liu G (2016) Adult degenerative scoliosis: can cobb angle on a supine posteroanterior radiograph be used to predict the cobb angle in a standing position?. Medicine (Baltimore) 95(6):e2732CrossRefGoogle Scholar
  15. 15.
    Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW, Geissler EK (2002) Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8(2):128–135CrossRefPubMedGoogle Scholar
  16. 16.
    Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, Sun J, Monahan-Earley RA, Shiojima I, Nagy JA, Lin MI, Walsh K, Dvorak AM, Briscoe DM, Neeman M, Sessa WC, Dvorak HF, Benjamin LE (2006) Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer Cell 10(2):159–170CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124(3):471–484CrossRefPubMedGoogle Scholar
  18. 18.
    Kanno H, Ozawa H, Sekiguchi A, Yamaya S, Tateda S, Yahata K, Itoi E (2012) The role of mTOR signaling pathway in spinal cord injury. Cell Cycle 11(17):3175–3179CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Zheng N, Ding X, Jahan R (2014) Low concentration of rapamycin inhibits hemangioma endothelial cell proliferation, migration, and vascular tumor formation in mice. Curr Ther Res Clin Exp 76:99–103CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Russo E, Andreozzi F, Iuliano R, Dattilo V, Procopio T, Fiume G, Mimmi S, Perrotti N, Citraro R, Sesti G, Constanti A, De Sarro G (2014) Early molecular and behavioral response to lipopolysaccharide in the WAG/Rij rat model of absence epilepsy and depressive-like behavior, involves interplay between AMPK, AKT/mTOR pathways and neuroinflammatory cytokine release. Brain Behav Immun 42:157–168CrossRefPubMedGoogle Scholar
  21. 21.
    Cho HJ, Park J, Lee HW, Lee YS, Kim JB (2004) Regulation of adipocyte differentiation and insulin action with rapamycin. Biochem Biophys Res Commun 321(4):942–948CrossRefPubMedGoogle Scholar
  22. 22.
    Vignot S, Faivre S, Aguirre D, Raymond E (2005) mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 16(4):525–537CrossRefPubMedGoogle Scholar
  23. 23.
    Levine B, Mizushima N, Virgin HW (2011) Autophagy in immunity and inflammation. Nature 469(7330):323–335CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Antonarakis ES, Carducci MA, Eisenberger MA (2010) Novel targeted therapeutics for metastatic castration-resistant prostate cancer. Cancer Lett 291(1):1–13CrossRefPubMedGoogle Scholar
  25. 25.
    Brennan-Speranza TC, Conigrave AD (2015) Osteocalcin: an osteoblast-derived polypeptide hormone that modulates whole body energy metabolism. Calcif Tissue Int 96(1):1–10CrossRefPubMedGoogle Scholar
  26. 26.
    Sun H, Kim JK, Mortensen R, Mutyaba LP, Hankenson KD, Krebsbach PH (2013) Osteoblast-targeted suppression of PPARgamma increases osteogenesis through activation of mTOR signaling. Stem Cells 31(10):2183–2192CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2016

Authors and Affiliations

  1. 1.Department of OrthopaedicsPeking University First HospitalBeijingChina

Personalised recommendations